Summary
The anti-anxiety medication Xanax XR in 3mg tablets has been recalled across the United States due to failing a quality test called dissolution specifications. The recall is classified as Class II by the FDA, meaning the issue could cause temporary health problems but serious effects are unlikely.
Key Facts
- Viatris Specialty LLC recalled Xanax XR 3mg tablets sold in 60-tablet bottles nationwide.
- The recall began on March 17 and expanded on April 16.
- The recall is due to "failed dissolution specifications," meaning the tablets may not dissolve properly as intended.
- The FDA labeled this as a Class II recall, indicating possible temporary or reversible health effects.
- Affected pills included those distributed between August 27, 2024, and May 29, 2025.
- The expiration date of the recalled batches is February 28, 2027, with lot number 8177156.
- Patients taking the recalled medication are advised to stop immediately.
- No adverse reactions related to this issue have been reported so far.
